Immunotherapy and pancreatic cancer: unique challenges and potential opportunities

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) remains a lethal malignancy with low survival rates.
• Despite successes in other cancers, immunotherapies have largely failed in PDAC, leading to its classification as non-immunogenic.
• The unique tumor microenvironment (TME) of PDAC, characterized by dense stroma and limited immune cell infiltration, contributes to treatment resistance.

Purpose of the Study:

• To review the challenges and opportunities presented by the PDAC tumor microenvironment (TME) for immunotherapy.
• To explore the complex interplay between stromal signals, immune cells, and tumor cells within the PDAC TME.
• To discuss ongoing clinical trials investigating novel combination strategies for PDAC treatment.

Main Methods:

• Literature review of preclinical and clinical studies on PDAC immunology and TME.
• Analysis of the biological mechanisms underlying immune evasion in PDAC.
• Synthesis of current research on therapeutic strategies targeting the PDAC TME.

Main Results:

• PDAC's TME presents significant barriers to effective anti-tumor immunity.
• The TME exhibits complex, context-dependent roles in tumor growth and metastasis.
• Emerging research highlights the potential for modulating the TME to enhance immunotherapy efficacy.

Conclusions:

• Overcoming PDAC treatment resistance requires a deeper understanding of its complex TME.
• Targeting the interplay within the TME is crucial for developing effective immunotherapeutic strategies.
• Future research and clinical trials should focus on combination therapies that prime the TME for immunotherapy.